!“#$%&‘()*+,–./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|} !“#$%&‘()*+,–./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}
Amazon (AMZN -0.66%) is building a constellation of 3,000-plus small “Amazon Leo” satellites to provide broadband internet service from low earth orbit. Blue Origin, Amazon’s Jeff Bezos-founded cousin company, wants to build its own constellation of 5,400 small satellites to provide similar communication services specifically for enterprise, data center, and government customers. And of course, there’s…
Dukascopy Profit Drops 58%; IG Resolves Login Issues Dukascopy Profit Drops 58%; IG Resolves Login Issues Dukascopy Profit Drops 58%; IG Resolves Login Issues Dukascopy Profit Drops 58%; IG Resolves Login Issues Dukascopy Profit Drops 58%; IG Resolves Login Issues Dukascopy Profit Drops 58%; IG Resolves Login Issues Today’s financial news recap covers Dukascopy reports…
SDC Capital Partners has signed a new office lease just south of Manhattan’s Union Square, Commercial Observer has learned. The global digital infrastructure investment firm is taking 22,531 square feet of office space at Savanna’s 799 Broadway, according to a source with knowledge of the deal. The lease seems to represent a minor relocation for…
Foreclosure Starts Rise 18 Percent in First Half of 2026; Average Days to Complete a Foreclosure Down Seventh Quarter in a Row; Foreclosure Activity Rises Year Over Year in June and Q2 2026 IRVINE, Calif. — July 16, 2026 — ATTOM, the leading provider of property data, AI-powered intelligence, and real estate analytics solutions, today…
Minutes Item 1: Welcome and Apologies Andrea Rosen (Chair, Bank of England) welcomed James Ellery (Goldman Sachs) and Oliver McCausland (FCA) to the Committee.Ms Rosen also welcomed Alina Ishmuratova (JPMorgan), Paul Robson (NatWest Markets) and Vasileios Gkionakis (Aviva Investors) as guest presenters; and Mark Wyatt (Barclays) as an observer.Ms Rosen announced that Alan Barnes (FCA),…
The FDA IND clearance supports the initiation of RiboX’s Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world’s first circular RNA-based in vivo CAR-T therapy achieving FDA IND clearance. RiboX expands its clinical-stage pipeline through its proprietary targeted LNP delivery platform. SHANGHAI and CAMBRIDGE,…